EMA Authorised: Velmetia (sitagliptin;metformin hydrochloride) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA has authorised Velmetia, a fixed-dose combination of sitagliptin and metformin hydrochloride, for the treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• METFORMIN HYDROCHLORIDE (Metformin hydrochloride)
• Sitagliptin (sitagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp & Dohme B.V.. Decision date: 26/11/2025